Chemotherapy News and Research

Latest Chemotherapy News and Research

Researchers discover new mechanism of DNA repair process

Tucked within its double-helix structure, DNA contains the chemical blueprint that guides all the processes that take place within the cell and are essential for life. Therefore, repairing damage and maintaining the integrity of its DNA is one of the cell's highest priorities.

4 Oct 2010

Stem cell research breakthrough

Australian researchers have grown new human stem cells outside the body and this may provide new hope to cancer patients and those with genetic disorders. The team found a way to manipulate the environment of blood-forming stem cells to make them multiply.

3 Oct 2010

FDA issues Complete Response Letter for Teva's Neutroval BLA

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Application (BLA) for Neutroval™ (granulocyte colony-stimulating factor) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

1 Oct 2010

Global phase IV study confirms efficacy of erlotinib in treatment of non-small cell lung cancer

Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.

1 Oct 2010

DMC recommends continuation of enrollment in Celsion's Phase III ThermoDox HEAT study for primary liver cancer

Celsion Corporation, a leading oncology drug development company, announced that after reviewing data from 401 patients enrolled in its pivotal Phase III ThermoDox ® clinical study (the HEAT study) for primary liver cancer, the Data Monitoring Committee (DMC) has unanimously recommended that the trial continue to enroll patients with the goal of reaching the 600 patients required to complete the study.

1 Oct 2010

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

Teva Pharmaceuticals Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC).

30 Sep 2010

Ontario Breast Screening Program encourages women to get mammograms

Before she joined the Ontario Breast Screening Program (OBSP), Margot McAuliffe couldn't remember the last time she'd thought about having a mammogram.

30 Sep 2010

Canadian Cancer Society alarmed by government inaction to establish national catastrophic drug insurance program

A large majority of Canadians - 85 per cent - say if they were diagnosed with cancer the cost of drugs would have a negative impact on their personal finances, according to poll results released today by the Canadian Cancer Society.

30 Sep 2010

Study shows immunotherapy improves survival rate in children with neuroblastoma

Using immunotherapy biologic agents that stimulate the body's immune system pediatric oncologists have achieved the first substantial increase in over a decade in cure rates for the childhood cancer neuroblastoma. A newly released study shows that the new treatment improved two-year survival rates by 20 percent, compared to standard treatment for an aggressive form of neuroblastoma, a cancer of the nervous system.

30 Sep 2010

New miRNA screening assay to detect early-stage colorectal cancer

A new microRNA (miRNA) screening assay detected the majority of early-stage colorectal cancers with good specificity and sensitivity. Our test has the potential to be safe, cheap, robust, accurate and of little or no inconvenience to the individual, and could, therefore, easily be integrated into national screening programs as part of an annual checkup,said Søren Jensby Nielsen, Ph.D., scientific manager, Diagnostic Product Development, Exiqon A/S

30 Sep 2010

Triple negative breast cancer patients with BRCA gene mutations have low risk of recurrence: Research

Patients with triple negative breast cancer that also have mutations in the BRCA gene appear to have a lower risk of recurrence, compared to those with the same disease without the deleterious genetic mutation, according to researchers at The University of Texas MD Anderson Cancer Center.

30 Sep 2010

Researchers discover treatment improves overall survival in pregnant women with breast cancer

Long associated with a worse outcome, researchers at The University of Texas MD Anderson Cancer Center have discovered that women treated for breast cancer while pregnant, in fact, have improved disease free survival and a trend for improved overall survival compared to non-pregnant women treated for the disease.

30 Sep 2010

New form of immunotherapy increases survival in children with neuroblastoma

Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years, according to researchers at the University of California, San Diego School of Medicine and fellow institutions. The percentage rose from 46 percent for children receiving a standard therapy to 66 percent for children receiving immunotherapy plus standard therapy, according to the study published in the Sept. 30, 2010 issue of the New England Journal of Medicine.

30 Sep 2010

Researchers report chemotherapy affects gray matter in breast cancer patients

Researchers at the Indiana University Melvin and Bren Simon Cancer Center have published the first report using imaging to show that changes in brain tissue can occur in breast cancer patients undergoing chemotherapy.

30 Sep 2010

SCT transplantation benefits in Hodgkin's lymphoma is unclear

It remains an unresolved question whether adult patients with Hodgkin's lymphoma, a certain type of lymph node cancer, benefit from allogeneic stem cell transplantation (SCT) with an unrelated donor. This is due to the fact that studies are lacking that compare this therapy with autologous transplantation or conventional chemotherapy without SCT.

30 Sep 2010

Scientists discover gut stem cells replacement mechanism

CANCER RESEARCH UK scientists have discovered that gut stem cells replace each other in a 'one in, one out' system, which is completely different to previously accepted theories.

30 Sep 2010

New immunotherapy regimen improves survival rate in children with neuroblastoma: Research

30 Sep 2010

Breakthrough neuroblastoma treatment

According to a new study the addition of an experimental immunotherapy drug to the standard regimen of care extended the lives and decreased the risk of a disease recurrence in children with high-risk neuroblastoma. This tumor most frequently originates in one of the adrenal glands, but can also develop in nerve tissues in the neck, chest, abdomen, or pelvis. It forms 12 percent of cancer-related deaths in children under the age of 15 and half of patients with this type of malignancy have the high-risk form.

29 Sep 2010

Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer

Medivation, Inc. and Astellas Pharma Inc. today announced treatment of the first patient in a second Phase 3 clinical trial of the investigational drug MDV3100, which expands the Phase 3 development of the novel, triple-acting oral androgen receptor antagonist into an earlier-stage patient population. Known as PREVAIL, the trial will evaluate MDV3100 in men with advanced prostate cancer who have not yet received chemotherapy. Initiation of the PREVAIL trial triggers a milestone payment to Medivation under its collaboration agreement with Astellas.

29 Sep 2010

Sanford-Burnham receives five-year core grant renewal from NCI

The Cancer Center at Sanford-Burnham Medical Research Institute (Sanford-Burnham) has received a five-year core grant renewal from the National Cancer Institute (NCI).

29 Sep 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Researchers discover new mechanism of DNA repair process

Stem cell research breakthrough

FDA issues Complete Response Letter for Teva's Neutroval BLA

Global phase IV study confirms efficacy of erlotinib in treatment of non-small cell lung cancer

DMC recommends continuation of enrollment in Celsion's Phase III ThermoDox HEAT study for primary liver cancer

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

Ontario Breast Screening Program encourages women to get mammograms

Canadian Cancer Society alarmed by government inaction to establish national catastrophic drug insurance program

Study shows immunotherapy improves survival rate in children with neuroblastoma

New miRNA screening assay to detect early-stage colorectal cancer

Triple negative breast cancer patients with BRCA gene mutations have low risk of recurrence: Research

Researchers discover treatment improves overall survival in pregnant women with breast cancer

New form of immunotherapy increases survival in children with neuroblastoma

Researchers report chemotherapy affects gray matter in breast cancer patients

SCT transplantation benefits in Hodgkin's lymphoma is unclear

Scientists discover gut stem cells replacement mechanism

New immunotherapy regimen improves survival rate in children with neuroblastoma: Research

Breakthrough neuroblastoma treatment

Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer

Sanford-Burnham receives five-year core grant renewal from NCI

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in